XML 68 R50.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Oct. 31, 2024
Property, Plant and Equipment [Line Items]            
Consolidation basis description   (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.        
Outstanding principal amount   $ 107,500,000       $ 30,000,000
Accounts receivable, net of allowances for credit losses   $ 416,000 $ 371,000      
Noncontrolling interest, description   Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights.        
Unrecognized tax benefits   $ 2,858,000 2,822,000      
Accrual for interest and penalties   69,000 40,000      
Recognized interest and penalties   69,000 40,000      
Cash, FDIC Insured Amount   250,000        
Recognized a loss on investment   (3,171,000) 3,092,000      
Accounts receivable, net   416,000        
Accounts receivable, contractual adjustments   19,731,000 14,875,000      
Accounts Receivable, after Allowance for Credit Loss   $ 20,147,000 $ 15,246,000      
Estimated useful life   20 years        
Restricted Stock Units (RSUs) [Member]            
Property, Plant and Equipment [Line Items]            
Vested RSU   211,020 215,539      
Stock Options, Unvested RSUs And Unvested PSUs [Member]            
Property, Plant and Equipment [Line Items]            
Stock options, unvested RSUs, and unvested PSUs   4,390,124 4,642,259      
Minimum [Member]            
Property, Plant and Equipment [Line Items]            
Property, plant and equipment, useful life   3 years        
Estimated useful life   2 years        
Minimum [Member] | New Drug Applications [Member]            
Property, Plant and Equipment [Line Items]            
Estimated useful life   4 years        
Maximum [Member]            
Property, Plant and Equipment [Line Items]            
Property, plant and equipment, useful life   5 years        
Estimated useful life   5 years        
Maximum [Member] | New Drug Applications [Member]            
Property, Plant and Equipment [Line Items]            
Estimated useful life   15 years        
Eton Pharmaceuticals, Inc. [Member]            
Property, Plant and Equipment [Line Items]            
Investment owned balance shares     1,982,000      
Ownership percentage     10.00%      
Proceeds from sale of equity $ 5,510,000          
Recognized a loss on investment $ 3,171,000          
Investment owned at fair value   $ 0 $ 8,681,000      
Melt Pharmaceuticals, Inc. [Member]            
Property, Plant and Equipment [Line Items]            
Ownership percentage   45.00%        
Reduction in investment         $ 0  
Investment interest rate       100.00%    
Melt Pharmaceuticals, Inc. [Member] | Common Stock [Member]            
Property, Plant and Equipment [Line Items]            
Investment owned balance shares   3,500,000        
Reduction in investment       $ 0    
Melt Pharmaceuticals, Inc. [Member] | Preferred Stock [Member]            
Property, Plant and Equipment [Line Items]            
Investment owned balance shares   2,334,256        
Reduction in investment     0      
Surface Ophthalmics, Inc. [Member]            
Property, Plant and Equipment [Line Items]            
Investment owned balance shares   3,500,000        
Ownership percentage   20.00%        
Surface Ophthalmics, Inc. [Member] | Common Stock [Member]            
Property, Plant and Equipment [Line Items]            
Reduction in investment         $ 0  
Eton Pharmaceuticals, Inc. [Member]            
Property, Plant and Equipment [Line Items]            
Investments related to change in fair market value of its investment     3,092,000      
Investment owned at fair value     8,681,000      
Melt Pharmaceuticals, Inc. [Member]            
Property, Plant and Equipment [Line Items]            
Due from related parties   $ 0 $ 89,000